Archive for the ‘HUYA Bioscience International’ Category

HUYA Bioscience International

February 26th, 2016 | Posted in 2016, HUYA Bioscience International

HUYA Bioscience International signed a licensing deal with Eisai, Japan,  worth up to $280 million which will grant the Japanese pharma an exclusive license to its anti-cancer compound, HBI-8000, in eight Asian nations: Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Thailand, and Vietnam. Eisai will hold exclusive rights to develop future indications, such as solid […]